These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2785444)

  • 1. Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal beta-lactamase.
    Stratton CW; Kernodle DS; Eades SC; Weeks LS
    Diagn Microbiol Infect Dis; 1989; 12(1):57-65. PubMed ID: 2785444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population analysis of susceptibility to cefotaxime and desacetyl-cefotaxime in Staphylococcus and Enterobacteriaceae.
    Hansen BG; Søgaard P
    Acta Pathol Microbiol Immunol Scand B; 1985 Jun; 93(3):243-7. PubMed ID: 3875967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks.
    Stevens DL; Bergstrom R; Gibbons A
    Diagn Microbiol Infect Dis; 1989; 12(1):73-80. PubMed ID: 2653715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reassessment of the activity of the third-generation cephalosporins against anaerobes and Staphylococcus aureus.
    Canawati HN
    Am J Surg; 1992 Oct; 164(4A Suppl):24S-27S. PubMed ID: 1443357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms.
    Aldridge KE; Weeks LS; Stratton CW; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(2):165-70. PubMed ID: 2752714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic antibacterial interaction of cefotaxime and desacetylcefotaxime.
    Molinari G; Saverino D; Paglia P; Debbia EA; Schito GC
    J Chemother; 1991 Feb; 3(1):6-12. PubMed ID: 2019866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.
    Aldridge KE
    Diagn Microbiol Infect Dis; 1989; 12(1):45-50. PubMed ID: 2714072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of cefotaxime/desacetylcefotaxime with two aminoglycosides against gram-negative pathogens: an example of interactive synergy.
    Jenkins SG
    Diagn Microbiol Infect Dis; 1989; 12(1):51-5. PubMed ID: 2714073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species.
    Canawati HN
    Diagn Microbiol Infect Dis; 1989; 12(1):33-7. PubMed ID: 2714070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus.
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T
    Antimicrob Agents Chemother; 1989 Mar; 33(3):331-5. PubMed ID: 2786369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.
    McDougal LK; Thornsberry C
    J Clin Microbiol; 1986 May; 23(5):832-9. PubMed ID: 3011847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of disk susceptibility testing of cefotaxime/desacetylcefotaxime.
    Fuchs PC; Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(1):81-5. PubMed ID: 2714075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of cefotaxime, desacetylcefotaxime, and the combination of the two.
    Friis H
    Diagn Microbiol Infect Dis; 1989; 12(1):67-72. PubMed ID: 2714074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation in an animal model and in vitro of the combination clavulanic acid and cephalosporins against beta-lactamase producing and nonproducing Staphylococcus aureus strains.
    de Sá Del Fiol F; Rocha De Mattos Filho T; Groppo FC
    Braz J Infect Dis; 2000 Feb; 4(1):36-42. PubMed ID: 10788844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro synergy between cefotaxime and its main metabolite, desacetylcefotaxime].
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T; Kawana R
    Jpn J Antibiot; 1988 May; 41(5):594-601. PubMed ID: 3216482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci.
    Jones RN; Barry AL; Packer RR
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):37S-46S. PubMed ID: 6086217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic activity of cefotaxime and desacetylcefotaxime against the Bacteroides fragilis group.
    Cornick NA; Gorbach SL
    Diagn Microbiol Infect Dis; 1988 Jun; 10(2):81-4. PubMed ID: 3224498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antistaphylococcal activity of amoxicillin and ticarcillin when combined with clavulanic acid. Evaluation of oxacillin-resistant and oxacillin-susceptible isolates.
    Barry AL
    Diagn Microbiol Infect Dis; 1990; 13(5):357-61. PubMed ID: 2282775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro comparison of the activity of cefotaxime and desacetylated cefotaxime and of their combination.
    Nanetti A; La Placa M
    J Chemother; 1990 Jun; 2(3):159-63. PubMed ID: 2380765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of cefotaxime alone and in combination with desacetylcefotaxime against Bacteroides fragilis.
    Wasilauskas BL
    Diagn Microbiol Infect Dis; 1989; 12(1):39-43. PubMed ID: 2714071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.